{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:49:59Z","timestamp":1787316599484,"version":"build-2736575974"},"reference-count":141,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2024,5,11]],"date-time":"2024-05-11T00:00:00Z","timestamp":1715385600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Inhaled ciprofloxacin (CFX) has been investigated as a treatment for lower respiratory tract infections (LRTIs) associated with cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD), and bronchiectasis. The challenges in CFX effectiveness for LRTI treatment include poor aqueous solubility and therapy resistance. CFX dry powder for inhalation (DPI) formulations were well-tolerated, showing a remarkable decline in overall bacterial burden compared to a placebo in bronchiectasis patients. Recent research using an inhalable powder combining Pseudomonas phage PEV20 with CFX exhibited a substantial reduction in bacterial density in mouse lungs infected with clinical P. aeruginosa strains and reduced inflammation. Currently, studies suggest that elevated biosynthesis of fatty acids could serve as a potential biomarker for detecting CFX resistance in LRTIs. Furthermore, inhaled CFX has successfully addressed various challenges associated with traditional CFX, including the incapacity to eliminate the pathogen, the recurrence of colonization, and the development of resistance. However, further exploration is needed to address three key unresolved issues: identifying the right patient group, determining the optimal treatment duration, and accurately assessing the risk of antibiotic resistance, with additional multicenter randomized controlled trials suggested to tackle these challenges. Importantly, future investigations will focus on the effectiveness of CFX DPI in bronchiectasis and COPD, aiming to differentiate prognoses between these two conditions. This review underscores the importance of CFX inhalable formulations against LRTIs in preclinical and clinical sectors, their challenges, recent advancements, and future perspectives.<\/jats:p>","DOI":"10.3390\/pharmaceutics16050648","type":"journal-article","created":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T10:26:36Z","timestamp":1715682396000},"page":"648","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Ciprofloxacin-Loaded Inhalable Formulations against Lower Respiratory Tract Infections: Challenges, Recent Advances, and Future Perspectives"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1210-454X","authenticated-orcid":false,"given":"Vijay Kumar","family":"Panthi","sequence":"first","affiliation":[{"name":"Pharmacy Discipline, School of Clinical Sciences, Queensland University of Technology (QUT), Brisbane, QLD 4001, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn E.","family":"Fairfull-Smith","sequence":"additional","affiliation":[{"name":"School of Chemistry and Physics, Faculty of Science, Queensland University of Technology (QUT), Brisbane, QLD 4001, Australia"},{"name":"Centre for Materials Science, Queensland University of Technology (QUT), Brisbane, QLD 4001, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6751-6915","authenticated-orcid":false,"given":"Nazrul","family":"Islam","sequence":"additional","affiliation":[{"name":"Pharmacy Discipline, School of Clinical Sciences, Queensland University of Technology (QUT), Brisbane, QLD 4001, Australia"},{"name":"Centre for Materials Science, Queensland University of Technology (QUT), Brisbane, QLD 4001, Australia"},{"name":"Centre for Immunology and Infection Control (CIIC), Queensland University of Technology (QUT), Brisbane, QLD 4001, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,5,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Sabuj, M.Z.R., Dargaville, T.R., Nissen, L., and Islam, N. (2021). Inhaled ciprofloxacin-loaded poly(2-ethyl-2-oxazoline) nanoparticles from dry powder inhaler formulation for the potential treatment of lower respiratory tract infections. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0261720"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"105517","DOI":"10.1016\/j.jddst.2024.105517","article-title":"Antibiotic loaded inhalable liposomal nanoparticles against lower respiratory tract infections: Challenges, recent advances, and future perspectives","volume":"94","author":"Panthi","year":"2024","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e00988-17","DOI":"10.1128\/AAC.00988-17","article-title":"Pharmacokinetic-Pharmacodynamic Target Attainment Analyses to Determine Optimal Dosing of Ceftazidime-Avibactam for the Treatment of Acute Pulmonary Exacerbations in Patients with Cystic Fibrosis","volume":"61","author":"Bensman","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"105022","DOI":"10.1016\/j.jddst.2023.105022","article-title":"Inhalation drug delivery in combating pulmonary infections: Advances and challenges","volume":"89","author":"Kumbhar","year":"2023","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Garc\u00eda Clemente, M., Olveira, C., Gir\u00f3n, R., M\u00e1iz, L., Sibila, O., Golpe, R., Men\u00e9ndez, R., Rodr\u00edguez, J., Barreiro, E., and Rodr\u00edguez Hermosa, J.L. (2022). Impact of Chronic Bronchial Infection by Staphylococcus aureus on Bronchiectasis. J. Clin. Med., 11.","DOI":"10.3390\/jcm11143960"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Shi, C., Guo, K., Zhang, L., Guo, Y., Feng, Y., Cviji\u0107, S., Cun, D., and Yang, M. (2023). In Vitro and In Vivo Evaluation of Inhalable Ciprofloxacin Sustained Release Formulations. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15092287"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.jcf.2020.05.008","article-title":"Pseudomonas aeruginosa antimicrobial susceptibility test (AST) results and pulmonary exacerbation treatment responses in cystic fibrosis","volume":"20","author":"VanDevanter","year":"2021","journal-title":"J. Cyst. Fibros."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"647","DOI":"10.4155\/ppa.13.47","article-title":"Inhaled antibiotics to treat lung infection","volume":"2","author":"Cipolla","year":"2013","journal-title":"Pharm. Pat. Anal."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1093\/jac\/46.5.669","article-title":"Application of fluoroquinolone pharmacodynamics","volume":"46","author":"Wright","year":"2000","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.addr.2014.08.013","article-title":"Inhaled antimicrobial therapy\u2014Barriers to effective treatment","volume":"85","author":"Weers","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1128\/AAC.38.3.547","article-title":"Treatment of severe pneumonia in hospitalized patients: Results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group","volume":"38","author":"Fink","year":"1994","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1001\/archinte.1989.00390100083020","article-title":"Evaluation of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections. Impact of plasma concentrations, organism, minimum inhibitory concentration, and clinical condition on bacterial eradication","volume":"149","author":"Peloquin","year":"1989","journal-title":"Arch. Intern. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.pupt.2018.03.005","article-title":"Ciprofloxacin Dry Powder for Inhalation (ciprofloxacin DPI): Technical design and features of an efficient drug\u2013device combination","volume":"50","author":"McShane","year":"2018","journal-title":"Pulm. Pharmacol. Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1080\/21678707.2016.1196129","article-title":"Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis","volume":"4","author":"Aksamit","year":"2016","journal-title":"Expert Opin. Orphan Drugs"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.4155\/tde.13.71","article-title":"Liposomal formulations for inhalation","volume":"4","author":"Cipolla","year":"2013","journal-title":"Ther. Deliv."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.carbpol.2017.01.073","article-title":"Solubility and bioavailability enhancement of ciprofloxacin by induced oval-shaped mono-6-deoxy-6-aminoethylamino-\u03b2-cyclodextrin","volume":"163","author":"Choi","year":"2017","journal-title":"Carbohydr. Polym."},{"key":"ref_17","first-page":"3011","article-title":"Safety and Pharmacokinetics of Multiple-Dose Ciprofloxacin Dry Powder for Inhalation in Patients with Moderate or Severe COPD","volume":"38","author":"Stass","year":"2011","journal-title":"Eur. Respir. J."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/j.clinthera.2013.08.003","article-title":"Tolerability and pharmacokinetic properties of ciprofloxacin dry powder for inhalation in patients with cystic fibrosis: A phase I, randomized, dose-escalation study","volume":"35","author":"Stass","year":"2013","journal-title":"Clin. Ther."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1089\/jamp.2013.1056","article-title":"Safety and pharmacokinetics of ciprofloxacin dry powder for inhalation in cystic fibrosis: A phase I, randomized, single-dose, dose-escalation study","volume":"28","author":"Stass","year":"2015","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s40261-013-0082-0","article-title":"Inhalation of a dry powder ciprofloxacin formulation in healthy subjects: A phase I study","volume":"33","author":"Stass","year":"2013","journal-title":"Clin. Drug Investig."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1025633","DOI":"10.3389\/fpubh.2022.1025633","article-title":"The resistance mechanisms of bacteria against ciprofloxacin and new approaches for enhancing the efficacy of this antibiotic","volume":"10","author":"Shariati","year":"2022","journal-title":"Front. Public Health"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"413","DOI":"10.2147\/IDR.S348643","article-title":"Different Nanotechnology Approaches for Ciprofloxacin Delivery Against Multidrug-Resistant Microbes","volume":"15","author":"Yayehrad","year":"2022","journal-title":"Infect. Drug Resist."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1183\/09031936.00071312","article-title":"Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: A phase II randomised study","volume":"41","author":"Wilson","year":"2013","journal-title":"Eur. Respir. J."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"4059","DOI":"10.2147\/DDDT.S168014","article-title":"Spotlight on inhaled ciprofloxacin and its potential in the treatment of non-cystic fibrosis bronchiectasis","volume":"12","author":"Chorepsima","year":"2018","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1007\/s13346-021-00954-1","article-title":"Nanoparticle-mediated pulmonary drug delivery: State of the art towards efficient treatment of recalcitrant respiratory tract bacterial infections","volume":"11","author":"Huang","year":"2021","journal-title":"Drug Deliv. Transl. Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/S1471-4914(02)02414-0","article-title":"Hyperacidification in cystic fibrosis: Links with lung disease and new prospects for treatment","volume":"8","author":"Poschet","year":"2002","journal-title":"Trends Mol. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1136\/thorax.57.11.926","article-title":"Airways in cystic fibrosis are acidified: Detection by exhaled breath condensate","volume":"57","author":"Tate","year":"2002","journal-title":"Thorax"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1021\/bm0609691","article-title":"Rheology of gastric mucin exhibits a pH-dependent sol\u2212gel transition","volume":"8","author":"Celli","year":"2007","journal-title":"Biomacromolecules"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.actbio.2020.11.019","article-title":"Nitrogen-containing bisphosphonate-loaded micro-arc oxidation coating for biodegradable magnesium alloy pellets inhibits osteosarcoma through targeting of the mevalonate pathway","volume":"121","author":"Li","year":"2021","journal-title":"Acta Biomater."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Panthi, V.K., Dua, K., Singh, S.K., Gupta, G., Hansbro, P.M., and Paudel, K.R. (2023). Nanoformulations-Based Metronomic Chemotherapy: Mechanism, Challenges, Recent Advances, and Future Perspectives. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15041192"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.chemphyslip.2014.09.002","article-title":"Composition, structure and mechanical properties define performance of pulmonary surfactant membranes and films","volume":"185","author":"Parra","year":"2015","journal-title":"Chem. Phys. Lipids"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.addr.2017.11.002","article-title":"The role of mucus as an invisible cloak to transepithelial drug delivery by nanoparticles","volume":"124","author":"Birch","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jcis.2019.02.088","article-title":"Qualitative and quantitative analysis of the biophysical interaction of inhaled nanoparticles with pulmonary surfactant by using quartz crystal microbalance with dissipation monitoring","volume":"545","author":"Wan","year":"2019","journal-title":"J. Colloid. Interface Sci."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/nrmicro2415","article-title":"The biofilm matrix","volume":"8","author":"Flemming","year":"2010","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.addr.2014.11.017","article-title":"Antimicrobial resistance, respiratory tract infections and role of biofilms in lung infections in cystic fibrosis patients","volume":"85","author":"Ciofu","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"9749474","DOI":"10.1155\/2021\/9749474","article-title":"Formulation and development of Serratiopeptidase enteric coated tablets and analytical method validation by UV Spectroscopy","volume":"2021","author":"Panthi","year":"2021","journal-title":"Int. J. Anal. Chem."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"124046","DOI":"10.1016\/j.ijpharm.2024.124046","article-title":"Liposomal drug delivery strategies to eradicate bacterial biofilms: Challenges, recent advances, and future perspectives","volume":"655","author":"Panthi","year":"2024","journal-title":"Int. J. Pharm."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1111\/bph.13664","article-title":"Targeting the hard to reach: Challenges and novel strategies in the treatment of intracellular bacterial infections","volume":"174","author":"Kamaruzzaman","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1155\/2022\/6889293","article-title":"Formulation and Development of Adapalene Topical Nanohydrogel Using Different Surfactants and Cosurfactants for Antiacne Activity: In Vitro and Ex Vivo Evaluation","volume":"2022","author":"Panthi","year":"2022","journal-title":"J. Nanomater."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.cell.2012.06.040","article-title":"Extracellular M. tuberculosis DNA targets bacteria for autophagy by activating the host DNA-sensing pathway","volume":"150","author":"Watson","year":"2012","journal-title":"Cell"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.ijantimicag.2014.02.009","article-title":"Nanocarriers for antibiotics: A promising solution to treat intracellular bacterial infections","volume":"43","author":"Abed","year":"2014","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.2217\/nnm.15.128","article-title":"Toward an optimized treatment of intracellular bacterial infections: Input of nanoparticulate drug delivery systems","volume":"10","author":"Gref","year":"2015","journal-title":"Nanomedicine"},{"key":"ref_43","unstructured":"Tokimatsu, I., Hiramatsu, K., Morimoto, T., Imai, H., Suzaki, Y., Stass, H., Okumura, K., and Kadota, J. (2011). B46. Inhaled and Systemic Anti-Inflammatory Therapy in Copd, American Thoracic Society."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"7911","DOI":"10.1007\/s11356-016-6054-1","article-title":"Biodegradation of antibiotic ciprofloxacin: Pathways, influential factors, and bacterial community structure","volume":"23","author":"Liao","year":"2016","journal-title":"Environ. Sci. Pollut. Res."},{"key":"ref_45","unstructured":"Stass, H., Nagelschmitz, J., Kappeler, D., and Weimann, B. (2013). A43. Chronic Obstructive Pulmonary Disease Treatment: Novel Agents and Safety Studies, American Thoracic Society."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s41030-015-0007-6","article-title":"Colobreathe\u00ae for the treatment of cystic fibrosis-associated pulmonary infections","volume":"1","author":"Schwarz","year":"2015","journal-title":"Pulm. Ther."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"708","DOI":"10.4187\/respcare.06290","article-title":"Aerosol Delivery Devices for Obstructive Lung Diseases","volume":"63","author":"Pleasants","year":"2018","journal-title":"Respir. Care"},{"key":"ref_48","unstructured":"Mishra, B., and Singh, J. (2020). Targeting Chronic Inflammatory Lung Diseases Using Advanced Drug Delivery Systems, Academic Press."},{"key":"ref_49","first-page":"699","article-title":"Aerosol delivery devices in the treatment of asthma","volume":"53","author":"Hess","year":"2008","journal-title":"Respir. Care"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1208\/s12249-019-1291-5","article-title":"Novel Inhalable Ciprofloxacin Dry Powders for Bronchiectasis Therapy: Mannitol-Silk Fibroin Binary Microparticles with High-Payload and Improved Aerosolized Properties","volume":"20","author":"Liu","year":"2019","journal-title":"AAPS PharmSciTech"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1016\/j.apsb.2021.05.015","article-title":"Pharmaceutical strategies to extend pulmonary exposure of inhaled medicines","volume":"11","author":"Guo","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"391","DOI":"10.2217\/nnm-2022-0281","article-title":"The significance of quercetin-loaded advanced nanoformulations for the management of diabetic wounds","volume":"18","author":"Panthi","year":"2023","journal-title":"Nanomedicine"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/jps.23795","article-title":"Development and characterization of an in vitro release assay for liposomal ciprofloxacin for inhalation","volume":"103","author":"Cipolla","year":"2014","journal-title":"J. Pharm. Sci."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ejpb.2013.06.024","article-title":"In vitro and ex vivo methods predict the enhanced lung residence time of liposomal ciprofloxacin formulations for nebulisation","volume":"86","author":"Ong","year":"2014","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1007\/s11095-012-0827-0","article-title":"Liposomal nanoparticles control the uptake of ciprofloxacin across respiratory epithelia","volume":"29","author":"Ong","year":"2012","journal-title":"Pharm. Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jconrel.2007.12.011","article-title":"Efficient drug targeting to rat alveolar macrophages by pulmonary administration of ciprofloxacin incorporated into mannosylated liposomes for treatment of respiratory intracellular parasitic infections","volume":"127","author":"Chono","year":"2008","journal-title":"J. Control Release"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"272","DOI":"10.3109\/03639045.2013.858740","article-title":"In-vitro and in-vivo evaluation of ciprofloxacin liposomes for pulmonary administration","volume":"41","author":"Liu","year":"2015","journal-title":"Drug Dev. Ind. Pharm."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"122667","DOI":"10.1016\/j.ijpharm.2023.122667","article-title":"Microfluidics assembly of inhalable liposomal ciprofloxacin characterised by an innovative in vitro pulmonary model","volume":"635","author":"Zhang","year":"2023","journal-title":"Int. J. Pharm."},{"key":"ref_59","unstructured":"Haworth, C., Wanner, A., Froehlich, J., O\u2019Neal, T., Davis, A., Gonda, I., and O\u2019Donnell, A. (2017). B14. Clinical Trials Across Pulmonary Disease, American Thoracic Society."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Maselli, D.J., Keyt, H., and Restrepo, M.I. (2017). Inhaled Antibiotic Therapy in Chronic Respiratory Diseases. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18051062"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s13346-016-0310-2","article-title":"Sustained distribution of aerosolized PEGylated liposomes in epithelial lining fluids on alveolar surfaces","volume":"6","author":"Kaneko","year":"2016","journal-title":"Drug Deliv. Transl. Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1007\/s13346-018-0550-4","article-title":"Lipid-based pulmonary delivery system: A review and future considerations of formulation strategies and limitations","volume":"8","author":"Ngan","year":"2018","journal-title":"Drug Deliv. Transl. Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"105314","DOI":"10.1016\/j.jddst.2023.105314","article-title":"Docetaxel-loaded nanoformulations delivery for breast cancer management: Challenges, recent advances, and future perspectives","volume":"92","author":"Panthi","year":"2024","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"36814","DOI":"10.1021\/acsami.8b16092","article-title":"Antibacterial Micelles with Vancomycin-Mediated Targeting and pH\/Lipase-Triggered Release of Antibiotics","volume":"10","author":"Chen","year":"2018","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Stancheva, R., Paunova-Krasteva, T., Topouzova-Hristova, T., Stoitsova, S., Petrov, P., and Haladjova, E. (2023). Ciprofloxacin-Loaded Mixed Polymeric Micelles as Antibiofilm Agents. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15041147"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/bit.20454","article-title":"Immobilized N-alkylated polyethylenimine avidly kills bacteria by rupturing cell membranes with no resistance developed","volume":"90","author":"Wang","year":"2005","journal-title":"Biotechnol. Bioeng."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.actbio.2018.08.038","article-title":"Nanocarriers with conjugated antimicrobials to eradicate pathogenic biofilms evaluated in murine in vivo and human ex vivo infection models","volume":"79","author":"Liu","year":"2018","journal-title":"Acta Biomater."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1007\/s00253-015-7126-8","article-title":"The anti-bacterial poly (caprolactone)-poly (quaternary ammonium salt) as drug delivery carriers","volume":"100","author":"Leng","year":"2016","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.nano.2014.08.004","article-title":"In vivo toxicity of cationic micelles and liposomes","volume":"11","author":"Knudsen","year":"2015","journal-title":"Nanomedicine"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1080\/10837450.2018.1545237","article-title":"Optimization of a dry powder inhaler of ciprofloxacin-loaded polymeric nanomicelles by spray drying process","volume":"24","author":"Farhangi","year":"2019","journal-title":"Pharm. Dev. Technol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s11671-008-9234-1","article-title":"Evaluation of Aerosol Delivery of Nanosuspension for Pre-clinical Pulmonary Drug Delivery","volume":"4","author":"Chiang","year":"2009","journal-title":"Nanoscale Res. Lett."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"104474","DOI":"10.1016\/j.jddst.2023.104474","article-title":"Pulmonary multidrug codelivery of curcumin nanosuspensions and ciprofloxacin with N-acetylcysteine for lung infection therapy","volume":"84","author":"Liu","year":"2023","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_73","first-page":"223","article-title":"Chapter 15\u2014Nanotechnological applications for the control of pulmonary infections","volume":"Volume 1","author":"Kon","year":"2016","journal-title":"The Microbiology of Respiratory System Infections"},{"key":"ref_74","first-page":"5","article-title":"Selection of excipients for the formulation of Ceftriaxone sodium loaded chitosan nanoparticle through drug-excipient compatibility testing","volume":"8","author":"Manimekalai","year":"2015","journal-title":"Int. J. PharmTech Res."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"116800","DOI":"10.1016\/j.carbpol.2020.116800","article-title":"A review on chitosan and its development as pulmonary particulate anti-infective and anti-cancer drug carriers","volume":"250","author":"Rasul","year":"2020","journal-title":"Carbohydr. Polym."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.mencom.2022.11.022","article-title":"Ciprofloxacin chitosan conjugate: Combined antibacterial effect and low toxicity","volume":"32","author":"Egorov","year":"2022","journal-title":"Mendeleev Commun."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Egorov, A.R., Kirichuk, A.A., Rubanik, V.V., Rubanik, V.V., Tskhovrebov, A.G., and Kritchenkov, A.S. (2023). Chitosan and Its Derivatives: Preparation and Antibacterial Properties. Materials, 16.","DOI":"10.3390\/ma16186076"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1208\/s12249-010-9486-9","article-title":"Evaluation of a nanoemulsion-based formulation for respiratory delivery of budesonide by nebulizers","volume":"11","author":"Amani","year":"2010","journal-title":"AAPS PharmSciTech"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1080\/10717544.2017.1384298","article-title":"Critical physicochemical and biological attributes of nanoemulsions for pulmonary delivery of rifampicin by nebulization technique in tuberculosis treatment","volume":"24","author":"Shah","year":"2017","journal-title":"Drug Deliv."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.2147\/IJN.S167958","article-title":"Enhanced oral absorption of pemetrexed by ion-pairing complex formation with deoxycholic acid derivative and multiple nanoemulsion formulations: Preparation, characterization, and in vivo oral bioavailability and anticancer effect","volume":"13","author":"Pangeni","year":"2018","journal-title":"Int. J. Nanomed."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"118578","DOI":"10.1016\/j.ijpharm.2019.118578","article-title":"In vitro antibacterial activity of ciprofloxacin loaded chitosan microparticles and their effects on human lung epithelial cells","volume":"569","author":"Kucukoglu","year":"2019","journal-title":"Int. J. Pharm."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"427","DOI":"10.15171\/apb.2017.051","article-title":"Nanoparticles of Chitosan Loaded Ciprofloxacin: Fabrication and Antimicrobial Activity","volume":"7","author":"Sobhani","year":"2017","journal-title":"Adv. Pharm. Bull."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.ijbiomac.2018.12.204","article-title":"Enhanced antibacterial activity of Egyptian local insects\u2019 chitosan-based nanoparticles loaded with ciprofloxacin-HCl","volume":"126","author":"Marei","year":"2019","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ajps.2019.02.001","article-title":"Critical physicochemical attributes of chitosan nanoparticles admixed lactose-PEG 3000 microparticles in pulmonary inhalation","volume":"15","author":"Alhajj","year":"2020","journal-title":"Asian J. Pharm. Sci."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Egorov, A.R., Kurliuk, A.V., Rubanik, V.V., Kirichuk, A.A., Khubiev, O., Golubev, R., Lobanov, N.N., Tskhovrebov, A.G., and Kritchenkov, A.S. (2022). Chitosan-Based Ciprofloxacin Extended Release Systems: Combined Synthetic and Pharmacological (In Vitro and In Vivo) Studies. Molecules, 27.","DOI":"10.3390\/molecules27248865"},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Shazly, G.A. (2017). Ciprofloxacin Controlled-Solid Lipid Nanoparticles: Characterization, In Vitro Release, and Antibacterial Activity Assessment. BioMed Res. Int., 2017.","DOI":"10.1155\/2017\/2120734"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ijpharm.2017.05.013","article-title":"Ciprofloxacin-loaded lipid-core nanocapsules as mucus penetrating drug delivery system intended for the treatment of bacterial infections in cystic fibrosis","volume":"527","author":"Torge","year":"2017","journal-title":"Int. J. Pharm."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"288","DOI":"10.4103\/1735-5362.235156","article-title":"Solid lipid nanoparticles and nanostructured lipid carriers as novel drug delivery systems: Applications, advantages and disadvantages","volume":"13","author":"Ghasemiyeh","year":"2018","journal-title":"Res. Pharm. Sci."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Liu, J., Meng, J., Cao, L., Li, Y., Deng, P., Pan, P., Hu, C., and Yang, H. (2019). Synthesis and investigations of ciprofloxacin loaded engineered selenium lipid nanocarriers for effective drug delivery system for preventing lung infections of interstitial lung disease. J. Photochem. Photobiol. B Biol., 197.","DOI":"10.1016\/j.jphotobiol.2019.05.007"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1007\/s40265-020-01359-z","article-title":"Inhaled Liposomal Antimicrobial Delivery in Lung Infections","volume":"80","author":"Bassetti","year":"2020","journal-title":"Drugs"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1136\/thoraxjnl-2013-203207","article-title":"Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): A randomised, double-blind, placebo-controlled trial","volume":"68","author":"Serisier","year":"2013","journal-title":"Thorax"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1089\/jamp.2007.0652","article-title":"Aerosolized antibiotics for non-cystic fibrosis bronchiectasis","volume":"21","author":"Rubin","year":"2008","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1164\/rccm.201203-0487OC","article-title":"Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis","volume":"186","author":"Chalmers","year":"2012","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S2213-2600(18)30427-2","article-title":"Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): Two phase 3, randomised controlled trials","volume":"7","author":"Haworth","year":"2019","journal-title":"Lancet Respir. Med."},{"key":"ref_95","first-page":"34","article-title":"Biomarkers in Cystic Fibrosis Lung Disease\u2014A Review","volume":"27","author":"Ciuca","year":"2020","journal-title":"Rom. J. Anaesth. Intensive Care"},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Su, Y.B., Tang, X.K., Zhu, L.P., Yang, K.X., Pan, L., Li, H., and Chen, Z.G. (2022). Enhanced Biosynthesis of Fatty Acids Contributes to Ciprofloxacin Resistance in Pseudomonas aeruginosa. Front. Microbiol., 13.","DOI":"10.3389\/fmicb.2022.845173"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"118915","DOI":"10.1016\/j.ijpharm.2019.118915","article-title":"Inhalable liposomal powder formulations for co-delivery of synergistic ciprofloxacin and colistin against multi-drug resistant gram-negative lung infections","volume":"575","author":"Yu","year":"2020","journal-title":"Int. J. Pharm."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"118616","DOI":"10.1016\/j.ijpharm.2019.118616","article-title":"Evaluation of co-delivery of colistin and ciprofloxacin in liposomes using an in vitro human lung epithelial cell model","volume":"569","author":"Chai","year":"2019","journal-title":"Int. J. Pharm."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.2147\/IJN.S286896","article-title":"Development of Inhalable Nanostructured Lipid Carriers for Ciprofloxacin for Noncystic Fibrosis Bronchiectasis Treatment","volume":"16","author":"Almurshedi","year":"2021","journal-title":"Int. J. Nanomed."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ejpb.2018.04.006","article-title":"Fabrication of inhaled hybrid silver\/ciprofloxacin nanoparticles with synergetic effect against Pseudomonas aeruginosa","volume":"128","author":"Kalgudi","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_101","first-page":"PA4120","article-title":"Inhalable Ciprofloxacin-Nanoplex (CIP-Np) combined with mannitol as a novel bronchiectasis therapeutic","volume":"50","author":"Tran","year":"2017","journal-title":"Eur. Respir. J."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.ijpharm.2018.06.017","article-title":"A new therapeutic avenue for bronchiectasis: Dry powder inhaler of ciprofloxacin nanoplex exhibits superior ex vivo mucus permeability and antibacterial efficacy to its native ciprofloxacin counterpart","volume":"547","author":"Tran","year":"2018","journal-title":"Int. J. Pharm."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.ejpb.2017.04.032","article-title":"Ciprofloxacin-loaded PLGA nanoparticles against cystic fibrosis P. aeruginosa lung infections","volume":"117","author":"Torge","year":"2017","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Hamblin, K.A., Armstrong, S.J., Barnes, K.B., Davies, C., Laws, T., Blanchard, J.D., Harding, S.V., and Atkins, H.S. (2017). Inhaled Liposomal Ciprofloxacin Protects against a Lethal Infection in a Murine Model of Pneumonic Plague. Front. Microbiol., 8.","DOI":"10.3389\/fmicb.2017.00091"},{"key":"ref_105","first-page":"100178","article-title":"PK-PD Evaluation of Inhaled Microparticles loaded with Ciprofloxacin-Copper complex in a Rat Model of Chronic Pseudomonas aeruginosa Lung Infection","volume":"5","author":"Tewes","year":"2023","journal-title":"Int. J. Pharm. X"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1021\/acs.molpharmaceut.5b00543","article-title":"Ciprofloxacin-Loaded Inorganic\u2013Organic Composite Microparticles To Treat Bacterial Lung Infection","volume":"13","author":"Tewes","year":"2016","journal-title":"Mol. Pharm."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.ejpb.2019.08.004","article-title":"Inhalable combination powder formulations of phage and ciprofloxacin for P. aeruginosa respiratory infections","volume":"142","author":"Lin","year":"2019","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"118543","DOI":"10.1016\/j.carbpol.2021.118543","article-title":"Dry powder formulation for pulmonary infections: Ciprofloxacin loaded in chitosan sub-micron particles generated by electrospray","volume":"273","author":"Arauzo","year":"2021","journal-title":"Carbohydr. Polym."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.2147\/DDDT.S116443","article-title":"Development of a microparticle-based dry powder inhalation formulation of ciprofloxacin hydrochloride applying the quality by design approach","volume":"10","author":"Karimi","year":"2016","journal-title":"Drug Des. Devel Ther."},{"key":"ref_110","first-page":"142","article-title":"Inhalable ciprofloxacin\/polymyxin B dry powders in respiratory infection therapy","volume":"2","author":"Xu","year":"2023","journal-title":"Acta Mater. Medica"},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Wang, J., Stegger, M., Moodley, A., and Yang, M. (2023). Drug Combination of Ciprofloxacin and Polymyxin B for the Treatment of Multidrug-Resistant Acinetobacter baumannii Infections: A Drug Pair Limiting the Development of Resistance. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15030720"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1080\/03639040801958421","article-title":"Efficient drug delivery to alveolar macrophages and lung epithelial lining fluid following pulmonary administration of liposomal ciprofloxacin in rats with pneumonia and estimation of its antibacterial effects","volume":"34","author":"Chono","year":"2008","journal-title":"Drug Dev. Ind. Pharm."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.1021\/acs.molpharmaceut.8b00445","article-title":"Improved Physical Stability and Aerosolization of Inhalable Amorphous Ciprofloxacin Powder Formulations by Incorporating Synergistic Colistin","volume":"15","author":"Shetty","year":"2018","journal-title":"Mol. Pharm."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1080\/03639045.2017.1318902","article-title":"Dry powders for the inhalation of ciprofloxacin or levofloxacin combined with a mucolytic agent for cystic fibrosis patients","volume":"43","author":"Sahin","year":"2017","journal-title":"Drug Dev. Ind. Pharm."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"121657","DOI":"10.1016\/j.ijpharm.2022.121657","article-title":"Development and characterization of a spray-dried inhalable ciprofloxacin-quercetin co-amorphous system","volume":"618","author":"Alhajj","year":"2022","journal-title":"Int. J. Pharm."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"e000100","DOI":"10.1136\/bmjresp-2015-000100","article-title":"Ciprofloxacin DPI: A randomised, placebo-controlled, phase IIb efficacy and safety study on cystic fibrosis","volume":"2","author":"Dorkin","year":"2015","journal-title":"BMJ Open Respir. Res."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"2000110","DOI":"10.1183\/13993003.00110-2020","article-title":"Changes in respiratory symptoms during 48-week treatment with ARD-3150 (inhaled liposomal ciprofloxacin) in bronchiectasis: Results from the ORBIT-3 and -4 studies","volume":"56","author":"Chalmers","year":"2020","journal-title":"Eur. Respir. J."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1702052","DOI":"10.1183\/13993003.02052-2017","article-title":"RESPIRE 1: A phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis","volume":"51","author":"Soyza","year":"2018","journal-title":"Eur. Respir. J."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1702053","DOI":"10.1183\/13993003.02053-2017","article-title":"RESPIRE 2: A phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis","volume":"51","author":"Aksamit","year":"2018","journal-title":"Eur. Respir. J."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1378\/chest.130.5.1503","article-title":"Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis","volume":"130","author":"Bilton","year":"2006","journal-title":"Chest"},{"key":"ref_121","first-page":"1925","article-title":"Multicenter, randomized, double-blind, placebo-controlled study (ORBIT 1) to evaluate the efficacy, safety, and tolerability of once daily ciprofloxacin for inhalation in the management of pseudomonas aeruginosa infections in patients with non-cystic fibrosis bronchiectasis","volume":"38","author":"Bilton","year":"2011","journal-title":"Eur. Respir. J."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ejpb.2019.09.002","article-title":"Challenges and strategies in drug delivery systems for treatment of pulmonary infections","volume":"144","author":"Ho","year":"2019","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_123","unstructured":"Wauthoz, N., and Amighi, K. (2015). Pulmonary Drug Delivery, John Wiley & Sons."},{"key":"ref_124","first-page":"181","article-title":"Measurements of deposition, lung surface area and lung fluid for simulation of inhaled compounds","volume":"7","author":"Mercuri","year":"2016","journal-title":"Front. Pharmacol."},{"key":"ref_125","unstructured":"Hastedt, J.E., B\u00e4ckman, P., Clark, A.R., Doub, W., Hickey, A., Hochhaus, G., Kuehl, P.J., Lehr, C.-M., Mauser, P., and McConville, J. (2015, January 16\u201317). Scope and Relevance of a Pulmonary Biopharmaceutical Classification System. Proceedings of the AAPS\/FDA\/USP Workshop, Baltimore, MD, USA."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/apm.12335","article-title":"Pseudomonas aeruginosa biofilm infections: From molecular biofilm biology to new treatment possibilities","volume":"122","year":"2014","journal-title":"Apmis"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1007\/s11095-017-2250-z","article-title":"Polymer\/amorphous salt solid dispersions of ciprofloxacin","volume":"34","author":"Mesallati","year":"2017","journal-title":"Pharm. Res."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s11095-017-2281-5","article-title":"Effects of moisture-induced crystallization on the aerosol performance of spray dried amorphous ciprofloxacin powder formulations","volume":"35","author":"Shetty","year":"2018","journal-title":"Pharm. Res."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1186\/s13054-016-1448-5","article-title":"Fundamentals of aerosol therapy in critical care","volume":"20","author":"Dhanani","year":"2016","journal-title":"Crit. Care"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1586\/eri.12.136","article-title":"Inhaled ciprofloxacin for chronic airways infections caused by Pseudomonas aeruginosa","volume":"10","year":"2012","journal-title":"Expert Rev. Anti-Infect. Ther."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"121388","DOI":"10.1016\/j.ijpharm.2021.121388","article-title":"Developing ciprofloxacin dry powder for inhalation: A story of challenges and rational design in the treatment of cystic fibrosis lung infection","volume":"613","author":"Alhajj","year":"2022","journal-title":"Int. J. Pharm."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.ejpb.2020.11.019","article-title":"Synergistic activity of phage PEV20-ciprofloxacin combination powder formulation-A proof-of-principle study in a P. aeruginosa lung infection model","volume":"158","author":"Lin","year":"2021","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"120974","DOI":"10.1016\/j.ijpharm.2021.120974","article-title":"The rough inhalable ciprofloxacin hydrochloride microparticles based on silk fibroin for non-cystic fibrosis bronchiectasis therapy with good biocompatibility","volume":"607","author":"Lin","year":"2021","journal-title":"Int. J. Pharm."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1089\/jamp.2015.1282","article-title":"Ciprofloxacin dry powder for inhalation in patients with non-cystic fibrosis bronchiectasis or chronic obstructive pulmonary disease, and in healthy volunteers","volume":"30","author":"Stass","year":"2017","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1111\/imj.15210","article-title":"Meta-analysis of efficacy and safety of inhaled ciprofloxacin in non-cystic fibrosis bronchiectasis patients","volume":"51","author":"Wang","year":"2021","journal-title":"Intern. Med. J."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1080\/17476348.2018.1500179","article-title":"The efficacy of inhaled antibiotics in non-cystic fibrosis bronchiectasis","volume":"12","author":"Amaro","year":"2018","journal-title":"Expert Rev. Respir. Med."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1021\/acs.molpharmaceut.7b00036","article-title":"Physical characterization of tobramycin inhalation powder: II. State diagram of an amorphous engineered particle formulation","volume":"14","author":"Miller","year":"2017","journal-title":"Mol. Pharm."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1177\/1753465813487412","article-title":"Efficacy of inhaled ciprofloxacin in the management of non-cystic fibrosis bronchiectasis","volume":"7","author":"Justo","year":"2013","journal-title":"Ther. Adv. Respir. Dis."},{"key":"ref_139","doi-asserted-by":"crossref","unstructured":"Plaunt, A.J., Nguyen, T.L., Corboz, M.R., Malinin, V.S., and Cipolla, D.C. (2022). Strategies to Overcome Biological Barriers Associated with Pulmonary Drug Delivery. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14020302"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1080\/17425255.2021.1836157","article-title":"The pharmacokinetics of antibiotics in cystic fibrosis","volume":"17","author":"Akkerman","year":"2021","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_141","doi-asserted-by":"crossref","unstructured":"Pangeni, R., Panthi, V.K., Yoon, I.S., and Park, J.W. (2018). Preparation, Characterization, and In Vivo Evaluation of an Oral Multiple Nanoemulsive System for Co-Delivery of Pemetrexed and Quercetin. Pharmaceutics, 10.","DOI":"10.3390\/pharmaceutics10030158"}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/16\/5\/648\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:44:13Z","timestamp":1760107453000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/16\/5\/648"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,11]]},"references-count":141,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,5]]}},"alternative-id":["pharmaceutics16050648"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics16050648","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,11]]}}}